Treatment Selection and Prioritization for the EJS ACT‐PD MAMS Trial Platform
Open Access
- 18 April 2025
- journal article
- Published by Wiley in Movement Disorders
- Vol. 40 (7) , 1307-1317
Abstract
Background: There are currently no disease‐modifying therapies (DMTs) registered for Parkinson's disease (PD). The Edmond J. Safra Accelerating Clinical Trials in Parkinson Disease (EJS ACT‐PD) initiative will expedite clinical assessment of putative DMTs through a multi‐arm multistage (MAMS) trial, testing several treatments against a common placebo arm and replacing unsuccessful therapies early.Objective: The objective of this study was to describe the treatment selection process for the EJS ACT‐PD clinical trial platform.Methods: A Treatment Selection Working Group (TSWG) identified compounds using complementary strategies, such as literature search, related initiatives (Cure Parkinson's International Linked Clinical Trials [iLCT] initiative), and expert suggestions. Compounds were classified into five mechanistic subgroups (mitochondrial, lysosomal, protein, inflammation, “other”). “Go/No‐Go” criteria and a scoring system covering preclinical, pharmacological, and clinical evidence were devised. Experts scored the candidates for quantitative rankings. Dossiers adapted from iLCT documents were produced for the top‐ranked compounds and in turn prioritized by the TSWG. Practical and logistical considerations from the Steering Committee (SC) guided the final decision. Patient and Public Involvement and Engagement representatives provided feedback throughout the process.Results: A total of 293 interventions were identified, 52 of which passed the “Go/No‐Go” criteria and were scored. Dossiers of the 14 top‐ranked compounds were submitted to the SC. Telmisartan, terazosin, and ursodeoxycholic acid were selected as the initial interventions.Conclusions: Drug selection in DMT PD MAMS trials requires consideration of scientific and practical issues. We present a robust system that can inform similar initiatives. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.Keywords
Funding Information
- Edmond J. Safra Philanthropic Foundation
This publication has 24 references indexed in Scilit:
- Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocolThe Lancet Oncology, 2023
- The Lessebo Effect in Disease Modification Trials in Parkinson's DiseaseMovement Disorders, 2023
- Multi-arm Multi-stage (MAMS) Platform Randomized Clinical Trials2022
- Dexamethasone in Hospitalized Patients with Covid-19New England Journal of Medicine, 2021
- The RECOVERY PlatformNew England Journal of Medicine, 2021
- Safety of Plasma Infusions in Parkinson's DiseaseMovement Disorders, 2020
- The REDCap consortium: Building an international community of software platform partnersJournal of Biomedical Informatics, 2019
- Abiraterone for Prostate Cancer Not Previously Treated with Hormone TherapyNew England Journal of Medicine, 2017
- Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics supportJournal of Biomedical Informatics, 2009
- STAMPEDE: Systemic Therapy for Advancing or Metastatic Prostate Cancer — A Multi-Arm Multi-Stage Randomised Controlled TrialClinical Oncology, 2008